Company / EPS (Diluted)
Organon & Co. EPS (Diluted) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
$3.99
FY2025
5-year range
$3.59 / $12.69
FY2021-FY2025
Trend
+11.1%
vs FY2024
Sector context
#14 of 204
Health Care
What the data says
Among 204 Health Care companies, Organon & Co. is in the top 7% for eps (diluted). EPS (Diluted) returned to growth in FY2025 after 3 years of decline, reaching $3.99.
Based on SEC 10-K filings.
3.99 in FY2025 with a 5-year CAGR of -14.1%. Top quartile in the Health Care sector.
Declined from $5.31 to $3.99 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -22.3%
- 5-Year CAGR
- -14.1%
- 10-Year CAGR
- -
Sector benchmark
Top 7% in Health CareTop 7% of 204This company $3.99 Sector average -$0.98
▼
+507.3% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 11.1% year-over-year.
- Ranks #14 out of 204 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score 0.69 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 55.3%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | $3.99 | +11.1% |
| FY2024 | $3.59 | -32.4% |
| FY2023 | $5.31 | -37.7% |
| FY2022 | $8.52 | -32.9% |
| FY2021 | $12.69 | +48.9% |
| FY2020 | $8.52 | -32.9% |
| FY2019 | $12.69 | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026